Psychotic Disorders clinical trials

Explore recruiting psychotic disorders clinical trials.

Recruiting psychotic disorders studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Psychotic Disorders trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Long-term outcomes and safety of repeated rituximab treatment in psychotic disorders – RITS-LONG

Sweden

Therapeutic exploratory (Phase II) EU CTIS Study details

Phase III randomized, multicenter open label clinical trial to evaluate the efficacy of immunomodulatory therapy in case of psychiatric disorders with proven dysimmunity. TIM-DePisT

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

Enhancing social skills in schizophrenia spectrum disorders – two-arm, double-blind, randomized clinical trial investigating oxytocin vs. placebo as an add-on to an individualized psychosocial treatment (OXY-APS)

Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

A 52-week, Phase 2, Open-label Trial to Evaluate the Long-term Safety and Tolerability of CVL-231 in Adult Participants With Schizophrenia

Hungary, Bulgaria

Therapeutic exploratory (Phase II) EU CTIS Study details

Does the glucagon-like peptide-1 receptor agonist semaglutide prevent deterioration of metabolic state in prediabetic or diabetic patients with schizophrenia treated with the antipsychotic compounds clozapine or olanzapine?

Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

A study comparing the new drugs PG511/PG521/PG531 produced by Celon Pharma SA with the drug PG203 in healthy volunteers.

Poland

Human Pharmacology (Phase I)- Bioequivalence Study EU CTIS Study details

Psychotic Disorders trials by city

Psychotic Disorders in Toronto Psychotic Disorders in Vancouver Psychotic Disorders in Montreal Psychotic Disorders in Calgary Psychotic Disorders in Edmonton Psychotic Disorders in Ottawa Psychotic Disorders in Winnipeg Psychotic Disorders in Quebec City Psychotic Disorders in Hamilton Psychotic Disorders in Kitchener Psychotic Disorders in London Psychotic Disorders in Halifax Psychotic Disorders in New York Psychotic Disorders in Los Angeles Psychotic Disorders in Chicago Psychotic Disorders in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease